Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
The New England Journal of Medicine
|
April 15, 2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
Fred Poordad, Christophe Hezode, Roger Trinh, et al.
Gastroenterology
|
November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial
Stefan Zeuzem, Thomas Berg, Edward Gane, et al.
Journal of Hepatology
|
August 6, 2005
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
Stefan Zeuzem, Jean-Michel Pawlotsky, Esther Lukasiewicz, et al.
Gastroenterology
|
October 9, 2007
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)
Massimo Pilli, Alessandro Zerbini, Amalia Penna, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection
Steven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Journal of Hepatology
|
March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti, Graham R Foster, Stanley Wang, et al.
Lancet (London, England)
|
December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Mark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Journal of Hepatology
|
October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial
Gregory J Dore, Jordan J Feld, Alex Thompson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
Tarik Asselah, Stanislas Pol, Christophe Hezode, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
The New England Journal of Medicine
|
April 15, 2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
Fred Poordad, Christophe Hezode, Roger Trinh, et al.
Gastroenterology
|
November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial
Stefan Zeuzem, Thomas Berg, Edward Gane, et al.
Journal of Hepatology
|
August 6, 2005
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
Stefan Zeuzem, Jean-Michel Pawlotsky, Esther Lukasiewicz, et al.
Gastroenterology
|
October 9, 2007
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)
Massimo Pilli, Alessandro Zerbini, Amalia Penna, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection
Steven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Journal of Hepatology
|
March 20, 2018
High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Massimo Puoti, Graham R Foster, Stanley Wang, et al.
Lancet (London, England)
|
December 4, 2014
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial
Mark Sulkowski, Christophe Hezode, Jan Gerstoft, et al.
Journal of Hepatology
|
October 27, 2019
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial
Gregory J Dore, Jordan J Feld, Alex Thompson, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
September 28, 2017
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis
Tarik Asselah, Kris V Kowdley, Neddie Zadeikis, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
November 26, 2019
Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study
Tarik Asselah, Stanislas Pol, Christophe Hezode, et al.
Page
of 4